P2RY12 and atrial fibrillation: In PIONEER-AF, the dual therapy arm (rivaroxaban 15 mg once daily + a P2Y12 inhibitor) showed a numerically higher rate of cardiovascular events in the subgroup of patients undergoing PCI on bifurcation lesions, as compared to the classical TAT arm including warfarin [3].